Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

DEA Says No to Schedule II for Marijuana

Posted on September 5th, 2016 by

Pharma R&D

law

This month, in response to petitions from the former governors of Rhode Island and Washington and from a psychiatric nurse in New Mexico, the U.S. Drug Enforcement Agency (DEA) announced its decision to keep marijuana classified as a Schedule I controlled substance. Continue reading “DEA Says No to Schedule II for Marijuana” »

What do Pharmacovigilance and Market Research Programs have in common?

Posted on September 2nd, 2016 by

Pharmacovigilance

R_D_Solutions_Blog_Docter_Taking_Notes_DIGITAL

If you want an example of why PV needs to be very closely involved in Patient Support Programs (PSP) or Market Research Programs (MRP), what happened recently to a very large pharmaceutical company should be a wake-up call for checking where you are on this topic. Continue reading “What do Pharmacovigilance and Market Research Programs have in common?” »

Is it time for Design Thinking to drive R&D?

Posted on August 31st, 2016 by

Pharma R&D

digitech

According to Jon Kolko (HBR 2015), the age of “design thinking” is here. Several high tech companies appear to be taking simple design principals in moving from selling products to providing services for their users or clients. Continue reading “Is it time for Design Thinking to drive R&D?” »

Smart Devices, Big Data, and the Value of Long-Term Research

Posted on August 29th, 2016 by

Pharma R&D

calendar

In a new feature in The Atlantic, author Jessa Gamble makes the case that Modern Medicine Is Too Reliant on Short-Term Studies, too often preferring the instant gratification that comes from a short study, only to find those results soon challenged by yet another short-term study.

Continue reading “Smart Devices, Big Data, and the Value of Long-Term Research” »

Impact of Precision Medicine and Genomics on Patient Treatment

Posted on August 26th, 2016 by

Chemistry

DNA MAck

In January of 2015, President Barack Obama launched the Precision Medicine Initiative, which brought to the forefront the growing understanding and need for individually tailored and customized treatments for patients.

Continue reading “Impact of Precision Medicine and Genomics on Patient Treatment” »

  1. 1
  2. 36
  3. 37
  4. 38
  5. 39
  6. 40
  7. 55


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.